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CmaxSS:MIC ratio, as a predictor of clinical response to intravenous tobramycin in cystic fibrosis patients with
Pseudomonas aeruginosa
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Introduction: Tobramycin kills Pseudomonas aeruginosa more effectively at a higher maximum steady-state tobramycin
level (CmaxSS) and where strains of P. aeruginosa have a lower minimum inhibitory concentration (MIC). Hence, the ratio of
CmaxSS:MIC may predict bacterial killing. The object of this study was to see if this ratio also predicts clinical effectiveness.
Methods: This was a sub-study of the TOPIC study. CF patients were randomly assigned to once or three times daily
tobramycin (approximately 10 mg/kg/24 h). All patients also received ceftazidime (approximately 150 mg/kg/24 h). This
report describes 14 patients where the CmaxSS was calculated by pharmacokinetic modelling and where MIC was measured
for the strains of P. aeruginosa in the patient’s sputum. FEV1 was measured at the beginning and end of a 14-day course of
intravenous antibiotics and the difference was calculated as percent baseline.
Results: There were 6 males and 8 females (median age 16 years). Eight received once daily and six thrice daily. The
median increase in FEV1 percent baseline after 2 weeks of intravenous antibiotics was 23%. The median MIC of the most
prevalent organism at the start of treatment was 1.5 and of the most tobramycin-resistant organism was 4.0. There was no
correlation between CmaxSS:MIC ratio for the most prevalent strain of P. aeruginosa and the percent change in FEV1
(Spearman’s rho=0.015, P=0.96) or for the same ratio calculated for the most resistant strain of P. aeruginosa and percent
change in FEV1 (Spearman’s rho=0.046, P=0.88).
Conclusions: We were unable to show a relationship between the ratio of CmaxSS:MIC and clinical outcome. A larger
study may help investigate this relationship more fully. This work is supported by CF Trust grant PJ467 and by Chiron.
